Ratings Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Real-time Estimate Cboe BZX Other stock markets 03:11:22 2024-05-28 pm EDT			5-day change	1st Jan Change
37.4 ^USD	+22.97%		+24.02%	+17.41%

May. 22	Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	MT
May. 22	Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ARCTURUS THERAPEUTICS HOLDINGS INC.	-3.55%	819M	D+
MODERNA, INC.	+67.53%	63.85B	B-
IQVIA HOLDINGS INC.	-0.77%	41.83B	B
LONZA GROUP AG	+43.79%	40.47B	A
CELLTRION, INC.	-10.87%	27.17B	C
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B	B
BIO-TECHNE CORPORATION	+4.70%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.41%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes